LYN and acute myeloid leukemia: SFKs inhibit the activity of the retinoic acid receptor alpha (RARα [27], and SFK inhibitors (PP2, dasatinib) enhanced ATRA-mediated cellular differentiation in an AML cell line and primary blasts via Lyn inhibition-mediated activation of RAF-1/MEK/ERK [28,29,30,31].